EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through alpha 4 beta 7 and its ligands and madcam



Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through alpha 4 beta 7 and its ligands and madcam



Official Gazette of the United States Patent & Trademark Office Patents 1269(4), Apr 22



The invention relates to the treatment of individuals suffering from a disease associated with leukocyte recruitment to the gastrointestinal tract or other tissues as a result of binding of leukocytes to gut-associated endothelium expressing the molecule MAdCAM (such as inflammatory bowel disease), comprising administering to the individual an effective amount of an antibody which inhibits the binding of leukocytes to endothelial MAdCAM.

(PDF 0-2 workdays service: $29.90)

Accession: 035980511

Download citation: RISBibTeXText



Related references

Modulation of inflammatory bowel disease in IL-2 knockout mice by inhibiting the alpha4beta7/MAdCAM-1 interaction. Immunology 92(SUPPL 1): 66, 1997

Human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) demonstrates structural and functional similarities to the alpha 4 beta 7-integrin binding domains of murine MAdCAM-1, but extreme divergence of mucin-like sequences. Journal of Immunology 156(8): 2851-2857, 1996

Interleukin-2 receptor alpha and beta chain expression by circulating alpha-beta and gamma-beta T cells inflammatory bowel disease. Digestive Diseases & Sciences 40(2): 291-295, 1995

Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha (PPAR-alpha) in the development of inflammatory bowel disease in mice. Laboratory Investigation; A Journal of Technical Methods and Pathology 84(12): 1643-1654, 2004

Interleukin-2 receptor alpha and beta chain expression by circulating alpha beta and gamma delta T cells in inflammatory bowel disease. Digestive Diseases and Sciences 40(2): 291-295, 1995

MAdCAM-1 mediates lymphocyte-endothelial cell adhesion in a murine model of inflammatory bowel disease. Gastroenterology 118(4 Suppl 2 Part 1): AGA A353, April, 2000

Glucocorticoids and IL-10, but not 6-MP, 5-ASA or sulfasalazine block endothelial expression of MAdCAM-1: Implications for inflammatory bowel disease therapy. Alimentary Pharmacology & Therapeutics 15(8): 1211-1218, August, 2001

MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). Hepatology 33(5): 1065-1072, 2001

Involvement of oxidative stress and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in inflammatory bowel disease. Journal of Clinical Biochemistry and Nutrition 48(2): 112-116, 2011

Loss of transforming growth factor beta signalling in the intestine contributes to tissue injury in inflammatory bowel disease. Gut 49(2): 190-198, 2001

LPAM-1 (integrin alpha 4 beta 7)-ligand binding: overlapping binding sites recognizing VCAM-1, MAdCAM-1 and CS-1 are blocked by fibrinogen, a fibronectin-like polymer and RGD-like cyclic peptides. European Journal of Immunology 28(3): 995-1004, 1998

Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 74(1): 185-195, 1993

Regulation of TNF-alpha and TNF-beta gene expression in inflammatory bowel disease. Gastroenterology 104(4 SUPPL ): A755, 1993